Free tool
FAERS Monitor: Halcion
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017892 or its brand name (Halcion, Triazolam). Reports on generic versions are filed under their own applications.
Reports
4,040
Serious
3,259
81% of reports
Hospitalization
1,627
Death reported
662
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug abuse336
- drug ineffective288
- toxicity to various agents220
- sopor208
- overdose182
- completed suicide172
- fatigue165
- nausea163
- malaise155
- drug interaction152
- fall144
- dizziness135
- anxiety132
- insomnia132
- somnolence130
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 94 |
| 2005 | 76 |
| 2006 | 76 |
| 2007 | 59 |
| 2008 | 67 |
| 2009 | 76 |
| 2010 | 119 |
| 2011 | 129 |
| 2012 | 164 |
| 2013 | 185 |
| 2014 | 225 |
| 2015 | 250 |
| 2016 | 317 |
| 2017 | 288 |
| 2018 | 301 |
| 2019 | 276 |
| 2020 | 229 |
| 2021 | 221 |
| 2022 | 177 |
| 2023 | 262 |
| 2024 | 160 |
| 2025 | 143 |
| 2026 | 146 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,119 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| soporSignal | 208 | 83.0 | 72.6 | 16,519 |
| drug abuseSignal | 336 | 21.1 | 19.0 | 6,411 |
| completed suicideSignal | 172 | 10.8 | 9.3 | 1,517 |
| toxicity to various agentsSignal | 220 | 6.8 | 6.0 | 1,090 |
| drug interactionSignal | 152 | 5.0 | 4.3 | 484 |
| overdoseSignal | 182 | 4.4 | 3.8 | 478 |
| somnolenceSignal | 130 | 3.4 | 2.8 | 215 |
| insomniaSignal | 132 | 2.6 | 2.2 | 128 |
| anxietySignal | 132 | 2.4 | 2.0 | 110 |
| fallSignal | 144 | 2.3 | 1.9 | 101 |
| malaise | 155 | 1.8 | 1.6 | 60 |
| dizziness | 135 | 1.4 | 1.2 | 16 |
| drug ineffective | 288 | 1.1 | 1.0 | 5 |
| fatigue | 165 | 1.1 | 1.0 | 2 |
| nausea | 163 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.